Table 2.
Costs, effects, and cost effectiveness of colorectal cancer screening programs over a lifetime horizon in the Ukraine
| Strategy | Mean cost (2012, US$) | Mean effects (QALYs) | Incremental cost (2012 US$) | Incremental effects (QALYs) | ICER | Mortality decrease |
|---|---|---|---|---|---|---|
| Colonoscopy every 10 years | 235 | 14.307 | N/A | N/A | Dominant | 73% |
| FOBT yearly | 247 | 14.295 | 13 | − 0.013 | Dominated | 61.6% |
| Sigmoidoscopy every 5 years with FOBT | 256 | 14.300 | 21 | − 0.008 | Dominated | 64% |
| No screening | 404 | 14.218 | 169 | − 0.084 | Dominated | Reference |
US United States, QALY quality adjusted life years, ICER incremental cost effectiveness ratios, FOBT fecal occult blood test